91 related articles for article (PubMed ID: 9037857)
1. [The use of biotechnological recombinant-mice in biological safety research].
Inoue T
Eisei Shikenjo Hokoku; 1996; (114):1-12. PubMed ID: 9037857
[TBL] [Abstract][Full Text] [Related]
2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
3. The use of biotechnical recombinant-mice to test the safety of potential carcinogenic pharmaceuticals.
Inoue T
J Toxicol Sci; 1995 Sep; 20(4):468-70. PubMed ID: 8531244
[No Abstract] [Full Text] [Related]
4. Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist.
Recio L; Everitt J
Comp Med; 2001 Oct; 51(5):399-405. PubMed ID: 11924798
[TBL] [Abstract][Full Text] [Related]
5. [Genetic modification of the mouse].
Andersson KB; Skålhegg BS
Tidsskr Nor Laegeforen; 1998 Oct; 118(25):3952-7. PubMed ID: 9830341
[TBL] [Abstract][Full Text] [Related]
6. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene.
Yamamoto S; Hayashi Y; Mitsumori K; Nomura T
Lab Anim Sci; 1997 Apr; 47(2):121-6. PubMed ID: 9150488
[TBL] [Abstract][Full Text] [Related]
7. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
[TBL] [Abstract][Full Text] [Related]
8. Animal models in biomedical research: transgenesis and gene targeting.
Roes J
Br J Hosp Med; 1997 Apr 16-May 6; 57(8):410-1. PubMed ID: 9274667
[No Abstract] [Full Text] [Related]
9. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH.
Wells MY; Williams ES
Regul Toxicol Pharmacol; 2009 Mar; 53(2):150-5. PubMed ID: 19126422
[TBL] [Abstract][Full Text] [Related]
10. The in vivo rodent test systems for assessment of carcinogenic potential.
van der Laan JW; Spindler P
Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
[TBL] [Abstract][Full Text] [Related]
11. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
[TBL] [Abstract][Full Text] [Related]
12. [Usefulness of transgenic mice in carcinogenicity tests].
Hayashi Y; Kodama Y; Fuji S
Jikken Dobutsu; 1993 Jul; 42(3):282-6. PubMed ID: 8354349
[No Abstract] [Full Text] [Related]
13. Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Nov; 404():1-303. PubMed ID: 12621514
[TBL] [Abstract][Full Text] [Related]
14. Investigations of clofibrate in alternative carcinogenicity models.
Santostefano MJ; Hoivik DJ; Miller RT
Int J Toxicol; 2005; 24(5):285-8. PubMed ID: 16257848
[No Abstract] [Full Text] [Related]
15. Transgenic mice in carcinogenicity testing.
Griesemer R; Tennant R
IARC Sci Publ; 1992; (116):429-36. PubMed ID: 1428092
[TBL] [Abstract][Full Text] [Related]
16. Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing.
Suemizu H; Muguruma K; Maruyama C; Tomisawa M; Kimura M; Hioki K; Shimozawa N; Ohnishi Y; Tamaoki N; Nomura T
Mol Carcinog; 2002 May; 34(1):1-9. PubMed ID: 12112317
[TBL] [Abstract][Full Text] [Related]
17. The utility of the K6/ODC transgenic mouse as an alternative short term dermal model for carcinogenicity testing of pharmaceuticals.
Miller TJ; Honchel R; Espandiari P; Knapton A; Zhang J; Sistare FD; Hanig JP
Regul Toxicol Pharmacol; 2008 Feb; 50(1):87-97. PubMed ID: 18069108
[TBL] [Abstract][Full Text] [Related]
18. Current issues in mouse genome engineering.
Glaser S; Anastassiadis K; Stewart AF
Nat Genet; 2005 Nov; 37(11):1187-93. PubMed ID: 16254565
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
20. Preclinical safety evaluation of recombinant human interleukin-10.
Rosenblum IY; Johnson RC; Schmahai TJ
Regul Toxicol Pharmacol; 2002 Feb; 35(1):56-71. PubMed ID: 11846636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]